GAMMA BIOLOGICALS INC

GAMMA BIOLOGICALS INC (CIK 317890) remains a specialist within the In Vitro & In Vivo Diagnostic Substances sector (SIC 2834), developing and distributing gamma globulin therapies, plasma-derived diagnostic reagents and support services that help hospital labs, transfusion centers, and biotech researchers detect immunological disorders. Operating without a public trading symbol, the company has historically targeted clinical customers who rely on precise serological reagents and custom assay development, pitching its low-volume expertise against larger supply networks. Regulatory pressure from the FDA, CLIA inspectors, and the complexities of maintaining plasma sourcing consents underscore the material risk profile, particularly as the firm continues to rely on dated disclosures—most recently a Form 8-K filed in September 1998—to demonstrate compliance and business continuity. Supply-chain concentration, evolving reimbursement rules and the need to align with stringent biopharma safety standards make near-term diligence critical, so readers should review the live SEC filings on Earnings Feed to stay informed.

Source: Earnings Feed research · last updated 11/24/2025